During the past several years there has been a recrudescence of interest in the metabolism of iron together with a new interest in the treatment of iron-deficiency anemia. This has been brought about because of the availability of new investigative tools and techniques and by the manufacture of new and effective parenteral iron products.It is the purpose of this paper to report on a clinical trial of an iron-dextran complex for intramuscular administration (Imferon), used in the treatment of iron-deficiency anemia in infants and children.
B. Materials and Methods
Sixty-five infants and children are included in this study. The ages range from 2 months to 7 years, with a mean age of 14 months. There are 37 boys and 28 girls. Of these, 51 are Caucasians, 6 are Spanish-Americans, 7 are Negroes, and 1 is Oriental. Twenty-five of these patients had birth weights under 2500 gm. In
BARTLETT WH, BEATTY EC. The Treatment of Iron-Deficiency Anemia in Children with Iron-Dextran. AMA Am J Dis Child. 1957;94(6):662–667. doi:10.1001/archpedi.1957.04030070074007
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: